Cadila Healthcare gains after settling patent litigation with Warner Chilcott
GenVec up 23.6% after-hours after RAC approves initiation of CGF166 phase I study
CytRx reaches new high on cancer study results
For daily banking news and anonymous message boards, check out the new site cafebanking.com.
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24h |
Increase |
|---|---|---|---|
| Aventis | 1 | 8 | 700 % |
| Avanir | 1 | 7 | 600 % |
| Athenahealth | 1 | 6 | 500 % |
| AGA Medical | 8 | 46 | 475 % |
| Allergan | 2 | 11 | 450 % |
| Wellpoint | 3 | 16 | 433 % |
| Celldex | 1 | 5 | 400 % |
| Array Biopharma | 1 | 4 | 300 % |
| Ariad Pharmaceuticals | 3 | 12 | 300 % |
| Divi's Laboratories | 1 | 4 | 300 % |
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| Endocyte | 1 | 18 | 1700 % |
| Deltex Medical | 1 | 15 | 1400 % |
| Corcept Therapeutics | 2 | 27 | 1250 % |
| CorMedix | 1 | 12 | 1100 % |
| GenVec | 5 | 54 | 980 % |
| Atrium Medical | 1 | 10 | 900 % |
| Ocera Therapeutics | 1 | 10 | 900 % |
| Celator | 1 | 10 | 900 % |
| Arigene | 2 | 19 | 850 % |
| ALK-Abello | 1 | 8 | 700 % |